MedTrace Logo

A Clinical Study of RSS0343 in Healthy Subjects

NCT07289464 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-01-14

No results posted yet for this study

Summary

This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of RSS0343 following multiple oral doses in healthy subjects, as well as its effects on the QT/QTc interval.

Conditions

  • Non-cystic Fibrosis Bronchiectasis

Interventions

DRUG

RSS0343 Tablets Placebo

RSS0343 tablets placebo, oral.

DRUG

RSS0343 Tablets

RSS0343 tablets, oral.

Sponsors & Collaborators

  • Reistone Biopharma Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-04
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07289464 on ClinicalTrials.gov